Comparative Pharmacology
Head-to-head clinical analysis: TROVAN versus VIGAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TROVAN versus VIGAMOX.
TROVAN vs VIGAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trovan (trovafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, preventing bacterial DNA replication.
200 mg IV once daily for 7-14 days for community-acquired pneumonia; 200 mg orally once daily for 7-14 days for acute exacerbation of chronic bronchitis
1 drop in affected eye(s) every 4 hours while awake for 7 days; may increase to 1 drop every 2 hours on day 1.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, supporting twice-daily dosing.
Terminal elimination half-life: 12-14 hours; clinically relevant for once-daily dosing
Renal (approximately 60% unchanged) and fecal/biliary (approximately 35% as unchanged drug and metabolites).
Renal: 70-80% unchanged; biliary/fecal: 15-20%
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)